RxDoctor Payments Data

Mark Operario, MD

Family Medicine · Columbia, LANPI 1720099344

Payments from drug & device makers

$493in general payments, 2019–2025

Across 30 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$177
  • AbbVie$79
  • Lilly USA, LLC$47
  • Pfizer$39
  • Xeris Pharmaceuticals, Inc.$38
  • GSK$36
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$44690%
  • Education$4710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$493 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$38,809
Medicare patients
95
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$186,221
OzempicSemaglutide176$171,113
JardianceEmpagliflozin198$137,952
TrulicityDulaglutide114$110,777
LinzessLinaclotide136$79,195
MounjaroTirzepatide66$74,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$55,860
FarxigaDapagliflozin Propanediol78$48,075
Breo ElliptaFluticasone/Vilanterol86$47,343
TradjentaLinagliptin91$46,599
Combivent RespimatIpratropium/Albuterol Sulfate50$31,907
JanuviaSitagliptin Phosphate42$30,403
AristadaAripiprazole Lauroxil12$27,897
EntrestoSacubitril/Valsartan35$23,504
MyrbetriqMirabegron61$20,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$186,221342 claims
Lilly USA, LLCTrulicity, Mounjaro$47$184,959180 claims
GSKTrelegy Ellipta, Breo Ellipta$36$103,203145 claims
AbbVieLinzess, Creon$79$88,853149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Columbia

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →